報價延遲最少15分鐘:2025/11/16 21:14 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.705 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-8.36/-21.39
|
|
企業價值
5.38M
|
| 資產負債 |
|
每股賬面淨值
4.13
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
4.94M
|
|
每股收益
1.47
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/11/16 21:14 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease. |
